Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Service d'aide à la décision clinique

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    12 0 0 0

Gynécologie Obstétrique & Fertilité
Volume 37, n° 9
pages 752-763 (septembre 2009)
Doi : 10.1016/j.gyobfe.2009.07.013
Recommandations pour la prise en charge du cancer de l’ovaire pendant la grossesse
French recommendations for ovarian cancer management during pregnancy

H. Marret a, , C. Lhommé b, F. Lécuru c, M. Canis d, J. Léveque e, F. Golfier f, P. Morice b

On the behalf of the French Working Group on Gynecological Cancers in Pregnancy


  Société française d’oncologie gynécologique.


  Société française de chirurgie pelvienne.


  Collège national des gynécologues obstétriciens français.

a Service de gynécologie, hôpital Bretonneau, centre hospitalo-universitaire de Tours, 37044 Tours cedex 1, France 
b Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France 
c Hôpital européen Gorges-Pompidou, 20, rue Leblanc, 75015 Paris, France 
d Hôtel-Dieu, CHU de Clermont-Ferrand, boulevard Léon-Malfreyt, 63058 Clermont-Ferrand, France 
e CHU de Rennes, 16, boulevard de Bulgarie, 35200 Rennes, France 
f Centre hospitalier Lyon-Sud, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France 

Auteur correspondant.

Evaluation of the fetus using prenatal ultrasound has resulted in increased detection of asymptomatic adnexal masses during pregnancy. Such masses are rarely malignant (1/10 000 to 1/50 000 pregnancies), but the possibility of borderline or cancer must be considered. It is a common assumption by both patients and physicians that if an ovarian cancer is diagnosed during pregnancy, treatment necessitates sacrificing the well-being of the fetus. However, in most cases, it is possible to offer appropriate treatment to the mother without placing the fetus at serious risk.

The care of a pregnant woman with cancer involves evaluation of sometimes competing maternal and fetal risks and benefits. These recommendation approaches attempt to balance these risks and benefits; however, they should be considered advisory and should not replace specific interdisciplinary consultation with specialists in maternal-fetal medicine, gynecologic oncology, and pediatrics, as well as imaging and pathology, as needed.

Second level ultrasound including Doppler is needed. MRI is not often necessary, and CA 125 is of low contribution. We suggest surgery be performed after 15 SA for ovarian masses which (1) persist into the second trimester, (2) are greater than 5 to 10 cm in diameter, or (3) have solid or mixed solid and cystic ultrasound characteristics. During antepartum surgical staging and debulking, homolateral salpingo-oophorectomy and peritoneal cytology and exploration are necessary. Women found to have advanced stage epithelial ovarian cancer should consider having completion of the debulking of the reproductive organs at the conclusion of the pregnancy. If chemotherapy is indicated, we recommend delaying administration, if possible, after the delivery or at least after 20 SA in order to minimize the potential fetal toxicity.

The full text of this article is available in PDF format.

Mots clés : Cancer de l’ovaire, Grossesse, Tumeur borderline, Kyste ovaire, Échographie, IRM, Chimiothérapie, Cœlioscopie

Keywords : Ovarian cancer, Borderline tumor, Ovarian cyst, Pregnancy, Ultrasound, MRI, Chemotherapy, Laparoscopy

1  Société française d’oncologie gynécologique.
2  Société française de chirurgie pelvienne.
3  Collège national des gynécologues obstétriciens français.

© 2009  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline